



Feasibility as a Service

Expert-led, data-driven feasibility to de-risk trial design and execution

Trial design and site selection decisions are **too costly to get wrong**.

Sponsors today face escalating challenges:



60%

increase

in protocol amendments since 2015¹



7

months longer for trial timelines, 2020–24²



\$40K

daily costs

for Phase II and III trials³



\$500K

in lost sales

daily³ from delays

¹ [New Benchmarks on Protocol Amendment Practices, Trends and their Impact on Clinical Trial Performance](#)


² <https://www.statista.com/statistics/1419920/biopharma-clinical-trial-cycle-time/>

³ [New Estimates on the Cost of a Delay Day in Drug Development](#)

Our Solution: Feasibility as a Service (FaaS)


FaaS is an **expert-led, data-driven** assessment that helps determine protocol viability, site selection strategies, recruitment plans, and mid-trial rescue decisions. Powered by Citeline's gold-standard **Sitetrove and Trialtrove** tools, our next-generation feasibility is **now delivered as a service** anchored in an **independent and objective** perspective to guide confident decisions.

With **dynamic**, decision-ready outputs, we help sponsors and their development partners **de-risk design, adapt in real time**, and keep studies on track without adding operational burden.



Flexible Feasibility for **Any Challenge** and **Any Phase**

- ✓ High-level planning supporting go/no go decisions
- ✓ Ideal country and site selection
- ✓ CRO pressure testing
- ✓ Referral network strategy
- ✓ Recruitment optimization
- ✓ Patient identification



Our feasibility approach combines a phased process with rich, connected data

Strategize



Whether your trial is in early planning stages or enrolling, FaaS services offer analysis at multiple stages for strategic decision making and outputs.

Analyze



Citeline will provide an analysis based on study status and sponsor needs leveraging Citeline's leading databases and SmartSolutions.

Analyze+



Based on study requirements and sponsor budget, Citeline will leverage real-world data and proprietary algorithms to enrich patient counts and profiles.

Recommend



Review analysis and/or recommendations based on experience, patient counts, trial capacity, and more.



199K
Sites



189
Countries



590K
Investigators



300M
US Lives
Claims Data



225M
US Lives
Lab Data



>40M
OUS Lives
EHR/EMR
Data



Proprietary
Performance
Data

... and
more

Case Study

Feasibility Rescue for a Phase III Oncology Trial in Renal Cell Carcinoma (RCC)

Overview

A leading CRO engaged Citeline to help assess underperformance in a global Phase III RCC trial. Through our analysis we:

- ✓ Identified that in **9 out of 10** selected countries, site-level enrollment lagged by an **average of 70%** below benchmark rates, based on recent RCC trial performance
- ✓ Recommended additional countries with **>5x higher enrollment potential** vs. current selected countries
- ✓ Provided a list of **120+** recommended investigators with high potential to support rescue efforts

Outcome

These insights helped the CRO secure the rescue engagement and are now guiding the post-rescue mitigation strategy.

Citeline. The data, the expertise, the independence you need to move your trial forward with confidence.

Learn more at [Citeline.com](https://www.citeline.com)